N Anthony Coles's Net Worth
$106 Million
Who is N Anthony Coles?
N Anthony Coles has an estimated net worth of $106 Million. This is based on reported shares across multiple companies, which include LABORATORY CORP OF AMERICA HOLDINGS, REGENERON PHARMACEUTICALS, INC., MCKESSON CORP, Cerevel Therapeutics Holdings, Inc., CRISPR Therapeutics AG, Campus Crest Communities, Inc., YUMANITY THERAPEUTICS, INC., VERTEX PHARMACEUTICALS INC / MA, NPS PHARMACEUTICALS INC, and ONYX PHARMACEUTICALS INC.
SEC CIK
N Anthony Coles's CIK is 0001197018
Past Insider Trading and Trends
2023 was N Anthony Coles's most active year for acquiring shares with 18 total transactions. N Anthony Coles's most active month to acquire stocks was the month of December. 2023 was N Anthony Coles's most active year for disposing of shares, totalling 32 transactions. N Anthony Coles's most active month to dispose stocks was the month of August. 2012 saw N Anthony Coles paying a total of $11,145,795.22 for 614,766 shares, this is the most they've acquired in one year. In 2012 N Anthony Coles cashed out on 800,771 shares for a total of $21,372,557.78, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
LABORATORY CORP OF AMERICA HOLDINGS (LH) Snapshot price: $223.91
InvestorN Anthony Coles owns 2,584 units of Common Stock which is worth $578,583.44. In the year 2011 N Anthony Coles filed a total of 5 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -7.71% | -216.00 |
—
|
—
| 2.58K |
Feb 15
| |||
Form 4
| +180.00% | 1.8K |
—
|
—
| 2.8K |
May 24
| |||
Form 4
| +233.33% | 700 |
—
|
—
| 1K |
May 11
| |||
Form 4
|
∞
| 300 |
—
|
—
| 300 |
Jan 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
REGENERON PHARMACEUTICALS, INC. (REGN) Snapshot price: $1131.5
InvestorN Anthony Coles owns 1,393 units of Common Stock which is worth $1,576,179.50. From 2017 to 2024 N Anthony Coles acquired a total of 33,099 shares in REGENERON PHARMACEUTICALS, INC. at a cost of $11,921,204.81, N also disposed a total of 31,706 shares of REGENERON PHARMACEUTICALS, INC. equalling to $20,622,962.24.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +10.73% | 135 |
—
|
—
| 1.39K |
Jan 2
| |||
Form 4
| +15.10% | 165 |
—
|
—
| 1.26K |
Jan 3
| |||
Form 4
|
—
|
0
|
$578.17 | -$1,565,411.58 | 1.09K |
Scheduled
|
Dec 28
| ||
Form 4
|
—
|
0
|
$476.84 | -$1,253,229.17 | 1.09K |
Scheduled
|
Sep 6
| ||
Form 4
| +21.18% | 191 |
—
|
—
| 1.09K |
Jan 3
| |||
Form 4
|
—
|
0
|
$512.49 | -$3,500,676.85 | 902 |
Scheduled
|
Sep 15
| ||
Form 4
|
—
|
0
|
$497.74 | -$1,827,180.00 | 902 |
Scheduled
|
Aug 17 - Aug 18
| ||
Form 4
|
—
|
0
|
$485.24 | -$559,060.00 | 902 |
Scheduled
|
Aug 13
| ||
Form 4
| +37.92% | 248 |
—
|
—
| 902 |
Jan 4
| |||
Form 4
| +1.71% | 11 |
$345.47 | $3,800.17 | 654 |
Nov 13
| |||
Form 4
| +99.07% | 320 |
—
|
—
| 643 |
Jan 2
| |||
Form 4
|
∞
| 323 |
—
|
—
| 323 |
Jan 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 27
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
MCKESSON CORP (MCK) Snapshot price: $504.17
InvestorN Anthony Coles used to own units in Common Stock but no longer holds any shares there. In the year 2014 N Anthony Coles filed a total of 11 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -2.45K |
$156.77 | -$384,559.26 |
0
|
Aug 17
| |||
Form 4
| +89.27% | 1.16K |
—
|
—
| 2.45K |
Jul 29
| |||
Form 4
|
∞
| 1.3K |
—
|
—
| 1.3K |
Jul 31
| |||
Form 4
| -100.00% | -1.35K |
$128.69 | -$173,731.50 |
0
|
Scheduled
|
Aug 31
| ||
Form 4
|
∞
| 1.35K |
—
|
—
| 1.35K |
Jul 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 26
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 29
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 15
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Cerevel Therapeutics Holdings, Inc. (CERE) No price found
CEO and ChairpersonN Anthony Coles owns 25,928 units of Common Stock. In the year 2023 N Anthony Coles acquired a total of 950,730 shares in Cerevel Therapeutics Holdings, Inc. at a cost of $3,237,500.00, N also disposed a total of 927,506 shares of Cerevel Therapeutics Holdings, Inc. equalling to $30,397,315.81.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
$22.34 | -$942,035.00 | 25.93K |
Jul 1
| |||
Form 4
| +65.80% | 10.29K |
—
|
—
| 25.93K |
Jun 5
| |||
Form 4
|
—
|
0
|
$22.06 | -$1,855,520.00 | 15.64K |
Jun 3
| |||
Form 4
|
—
|
0
|
$22.80 | -$1,930,125.00 | 15.64K |
May 10
| |||
Form 4
|
—
|
0
|
$22.92 | -$1,941,640.00 | 15.64K |
Apr 1
| |||
Form 4
|
—
|
0
|
$22.26 | -$1,875,550.00 | 15.64K |
Mar 4
| |||
Form 4
|
—
|
0
|
$22.33 | -$1,882,890.00 | 15.64K |
Feb 29
| |||
Form 4
| +478.33% | 12.93K |
$41.54 | -$104,109.51 | 15.64K |
Feb 6 - Feb 7
| |||
Form 4
|
—
|
0
|
$22.87 | -$1,936,815.00 | 2.7K |
Jan 2
| |||
Form 4
|
—
|
0
|
$14.32 | -$493,571.28 | 2.7K |
Nov 14
| |||
Form 4
|
—
|
0
|
$14.26 | -$584,955.24 | 2.7K |
Nov 7 - Nov 8
| |||
Form 4
|
—
|
0
|
$14.42 | -$2,183,697.46 | 2.7K |
Nov 2 - Nov 3
| |||
Form 4
|
—
|
0
|
$13.79 | -$1,028,415.00 | 2.7K |
Sep 7
| |||
Form 4
|
—
|
0
|
$16.77 | -$1,326,340.00 | 2.7K |
Jul 11
| |||
Form 4
|
—
|
0
|
$18.05 | -$1,455,070.00 | 2.7K |
Jun 1
| |||
Form 4
|
—
|
0
|
$17.49 | -$1,398,433.57 | 2.7K |
Scheduled
|
May 4
| ||
Form 4
|
—
|
0
|
$14.28 | -$1,078,130.00 | 2.7K |
Apr 11
| |||
Form 4
|
—
|
0
|
$15.31 | -$1,180,946.80 | 2.7K |
Scheduled
|
Mar 2 - Mar 3
| ||
Form 4
|
—
|
0
|
$18.32 | -$1,481,400.61 | 2.7K |
Scheduled
|
Feb 6 - Feb 7
| ||
Form 4
|
—
|
0
|
$16.72 | -$1,321,871.30 | 2.7K |
Scheduled
|
Jan 5
| ||
Form 4
|
—
|
0
|
$15.09 | -$1,158,300.05 | 2.7K |
Scheduled
|
Dec 9
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 28
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CRISPR Therapeutics AG (CRSP) Snapshot price: $44.9
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 31
| |||
Form 4
| +100.00% | 70K |
$14.00 | $980,000.00 | 140K |
Oct 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||